LENSAR® Announces Termination of Merger Agreement with Alcon Research, LLC
Rhea-AI Summary
LENSAR (Nasdaq: LNSR) announced termination of its merger agreement with Alcon Research, LLC, after the Federal Trade Commission indicated it intends to seek to enjoin the acquisition. The companies mutually agreed to end the deal because required U.S. regulatory approvals were unlikely by the April 23, 2026 outside date (or extended July 23, 2026).
The company will retain the $10.0 million deposit from the merger agreement and plans to report fourth quarter and full-year 2025 results and a strategic update on March 31, 2026, including a conference call at 8:30 a.m. ET.
Positive
- Retains $10.0 million deposit from terminated merger
- Plans to report Q4 and full-year 2025 results on March 31, 2026
- Management emphasizes continued growth of ALLY Robotic Cataract Laser System
- Expanded footprint and documented procedure growth since 2022
Negative
- Merger agreement with Alcon terminated due to FTC challenge
- Required U.S. regulatory approvals unlikely by April 23, 2026 or July 23, 2026
- Loss of proposed strategic combination with Alcon could affect scale plans
News Market Reaction – LNSR
On the day this news was published, LNSR declined 32.85%, reflecting a significant negative market reaction. Argus tracked a trough of -27.1% from its starting point during tracking. Our momentum scanner triggered 45 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $60M from the company's valuation, bringing the market cap to $122.55M at that time. Trading volume was exceptionally heavy at 17.5x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LNSR gained 4.31% with elevated volume, while peers were mixed: ARAY +7.01%, PROF +1.96%, SGHT +1.08%, RPID +2.06%, and MXCT -2.43%. Only one peer (OWLT +3.27%) appeared on the momentum scanner, supporting a stock-specific move rather than a broad sector rotation.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Acquisition status update | Positive | -2.3% | FTC Second Request update and expectation of closing in first half 2026. |
| Mar 24 | Acquisition announcement | Positive | -3.9% | Alcon’s definitive agreement to acquire LENSAR with cash and CVR consideration. |
| Mar 24 | Acquisition valuation details | Positive | -3.9% | Further details on per-share consideration and procedure-based contingent payout. |
Acquisition-related headlines for LNSR have historically been followed by negative price reactions despite ostensibly positive deal terms, suggesting a pattern of downside moves on M&A news.
Over the past year, LNSR’s major milestones have centered on its proposed acquisition by Alcon. The initial merger agreement on Mar 24, 2025 outlined cash and contingent consideration, yet shares fell about 4%. A later FTC-related update on Feb 25, 2026 also saw a modest decline. Against this backdrop, today’s termination of the merger comes after repeated regulatory hurdles, marking a major shift from the prior acquisition-focused narrative.
Historical Comparison
Past acquisition headlines for LNSR (3 events) saw an average move of -3.38%. Against that backdrop, the current market reaction contrasts with the typical negative response to prior Alcon-related announcements.
Acquisition-related news has progressed from Alcon’s initial agreement and detailed valuation terms in March 2025 to an FTC-driven status update in February 2026. Today’s announcement that the merger agreement was terminated marks a break from this earlier trajectory of anticipated completion.
Market Pulse Summary
The stock dropped -32.9% in the session following this news. A negative reaction despite retention of the $10.0 million deposit would fit concerns seen around prior acquisition headlines, which averaged moves of about -3.38%. The decline could reflect uncertainty around LNSR’s standalone outlook following the terminated Alcon deal. With results and a strategic update scheduled for March 31, 2026, attention may focus on growth, profitability trends, and how the company plans to fund and scale its ALLY platform.
Key Terms
federal trade commission regulatory
merger agreement regulatory
outside date regulatory
AI-generated analysis. Not financial advice.
Company to Report Fourth Quarter Financial Results and Provide Strategic Update on March 31, 2026
ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an agreement with Alcon Research, LLC (“Alcon”) to terminate the merger agreement between the parties.
We understand that the Federal Trade Commission intends to seek to enjoin the acquisition contemplated by the merger agreement. The Company and Alcon mutually agreed that terminating the merger agreement at this time is in the best interest of both companies, as the required closing condition of receiving necessary U.S. regulatory approvals is unlikely to be met by the merger agreement’s outside date of April 23, 2026 or the potential extended outside date of July 23, 2026. The Company will retain the
“While we are disappointed with this outcome and the FTC’s intention to challenge the proposed transaction, we remain committed to advancing the field of cataract surgery through the continued market growth of our ALLY Robotic Cataract Laser System™. Since its commercial introduction in 2022, we believe it has become clearer every day that ALLY is the future of refractive cataract surgery. With ALLY, we were able to significantly extend our technology leadership position, established on the strength of our previous-generation LLS platform. We have expanded our footprint and LENSAR’s influence in the space, which supported market share gains and significant procedure growth. Our team is committed to realizing the full potential of our innovation and capturing the significant untapped opportunity that exists in the market we serve,” said Nick Curtis, President and CEO of LENSAR. “We are focused on continuing to drive the expansion of ALLY’s global installed base and procedure volumes, and creating long-term value for patients, our surgeon partners and shareholders. We will share more detail on our strategy when we release our financial results on March 31, 2026.”
Additional Information:
LENSAR plans to report fourth quarter and full-year 2025 financial results and additional details on its go-forward strategy on Tuesday, March 31, 2026, with a press release to be issued prior to the open of trading. The Company will host a conference call on March 31 at 8:30 a.m. Eastern Time. Details on how to access the conference call will be provided in an upcoming announcement.
About LENSAR
LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR’s proprietary
Streamline® software technology, designed to guide surgeons to achieve better outcomes.
Forward-looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “target,” “will,” “would,” or the negative thereof and similar words and expressions.
Forward-looking statements are based on management’s current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: (i) risks related to disruption of management time from ongoing business operations due to the terminated merger with Alcon (the “Terminated Merger”); (ii) the risk that any announcements relating to the Terminated Merger could have adverse effects on the market price of the Company’s common stock; (iii) the significant costs, expenses and fees for professional services and other transaction costs in connection with the Terminated Merger and the risk that the deposit from Alcon retained by the Company is insufficient to cover such costs, expenses and fees; (iv) the risk of any litigation related to the Terminated Merger; (v) the risk that the Terminated Merger could have an adverse effect on the ability of the Company to retain and maintain relationships with customers, suppliers and other business partners and retain and hire key personnel and on its operating results and business generally; (vi) the risks inherent in Company’s ability to grow its business; and (vii) the Company’s ability to obtain financing on favorable terms, or at all. In addition, a number of other important factors could cause the Company’s actual future results and other future circumstances to differ materially from those expressed in any forward-looking statements, including but not limited to the other important factors that are disclosed under the heading “Risk Factors” contained in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in its other filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, to be filed with the SEC, each accessible on the SEC’s website at www.sec.gov and the Investor Relations section of the Company’s website at https://ir.lensar.com.
All forward-looking statements are expressly qualified in their entirety by such factors. Except as required by law, the Company undertakes no obligation to publicly update or review any forward-looking statement, whether because of new information, future developments or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
| Contacts: | Lee Roth |
| Thomas R. Staab, II, CFO | Burns McClellan for LENSAR |
| ir.contact@lensar.com | lroth@burnsmc.com |
Source: LENSAR, Inc.
FAQ
Why did LENSAR (LNSR) terminate the merger agreement with Alcon on March 16, 2026?
Will LENSAR (LNSR) keep any funds from the terminated Alcon merger?
When will LENSAR (LNSR) report financial results and provide a strategic update?
How does LENSAR describe the commercial performance of its ALLY system after the terminated merger?
What regulatory action influenced LENSAR and Alcon to terminate their merger agreement?
